Financial Toxicity Related to Cancer Diagnosis and Tretment in Adolescents and Young AdultsFINCARE-YoungNCT07314801
FINancial Toxicity and CAncer REcovery in YOUNG Adults
An observational study of Financial Toxicity Related to Cancer Diagnosis and Tretment in Adolescents and Young Adults, run by University Medical Center Goettingen at 1 site in Germany.
Trial summary
The FINCARE-Young study aims to investigate the extent and development of financial toxicity in adolescents and young adults with cancer. The primary purpose of this study is to assess the level of financial burden experienced during the acute phase of cancer treatment and after completion of therapy, and to analyze… Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Financial Toxicity Related to Cancer Diagnosis and Tretment in Adolescents and Young Adults
- How many people
- 300 participants
- Where
- 1 siteGermany
- Study dates
- Dec 2025to Apr 2026
- How long will I take part?
- 1 Year
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Study population: The study population will be selected from adolescents and young adults with a history of cancer who were treated at the University Medical Center Göttingen, a tertiary care academic hospital in Germany. Potential participants are identified through institutional clinical databases and electronic medical records. The source population includes individuals who received oncological care across all cancer entities within this center over the defined study period and who can be contacted for follow-up after completion of therapy.
Who may be able to join
- Age 18 to 39 years at the time of initial cancer diagnosis
- Diagnosis of a malignant neoplasm
- Receipt of oncological treatment at the University Medical Center Göttingen
- Completion of primary cancer therapy at the time of study participation
- Initial diagnosis between 2014 and 2024
- Ability to provide informed consent
- Sufficient German language skills to participate in a telephone interview and complete questionnaires
Who cannot join
- Age below 18 years or above 39 years at the time of initial cancer diagnosis
- No history of malignant disease
- Ongoing primary cancer treatment at the time of study participation
- Severe cognitive impairment or psychiatric condition preventing reliable participation
- Insufficient German language proficiency to complete interviews or questionnaires
- Withdrawal of informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
The FINCARE-Young study aims to investigate the extent and development of financial toxicity in adolescents and young adults with cancer. The primary purpose of this study is to assess the level of financial burden experienced during the acute phase of cancer treatment and after completion of therapy, and to analyze changes over time. In addition, the study seeks to identify sociodemographic, clinical, and socioeconomic factors associated with financial toxicity, as well as its impact on employment and social reintegration. By focusing on young adult cancer survivors, this study addresses an underexplored population and seeks to generate evidence to improve supportive care strategies and reduce long-term financial consequences of cancer.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Adolescents and Young Adults with Cancer | This cohort consists of adolescents and young adults aged 18 to 39 years at the time of initial cancer diagnosis who received oncological treatment at a single tertiary care center. Participants have completed their primary cancer therapy and are assessed retrospectively and prospectively. The study does not involve any therapeutic intervention. Data are collected through structured telephone interviews and standardized questionnaires, complemented by clinical data extracted from electronic medical records. The focus of the cohort is to evaluate financial toxicity, socioeconomic factors, and employment-related outcomes following cancer treatment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Financial toxicity
Financial toxicity, assessed using the Comprehensive Score for Financial Toxicity (COST) questionnaire, measured during the acute phase of cancer treatment and at the time of study participation, including change over time.
Measured: From the acute phase of cancer treatment to the time of study participation after completion of therapy (retrospective assessment of treatment period and current assessment at follow-up), assessed only at one time point at study enrollment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jan 2026
- Study startDec 2025 (estimated)
- Primary completionApr 2026 (estimated)
- Study completionApr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Financial Toxicity Related to Cancer Diagnosis and Tretment in Adolescents and Young AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 300 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- University Medical Center Goettingen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Dr. Rami El Shafie, University Medical Center Goettingen
- Investigators
- Rami El Shafie, Prof. Dr., Principal investigator, University Medicine Göttingen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07314801
- Sponsor's protocol ID
- 20/7/25
- Acronym
- FINCARE-Young
- Status last verified
- Dec 2025
- First submitted
- 18 Dec 2025
- Last updated
- 2 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because the study involves highly sensitive personal, medical, and socioeconomic information. Sharing individual-level data could pose a risk to participant privacy and confidentiality, even after pseudonymization, and is therefore not planned.